논문KCI 등재
Bridging the Gap Between Trial Adverse Events and Real-World Data
2
조회
0
다운로드
0
인용
0
참고문헌
주제분류의학일반
참고문헌 (4)
- Jeon Y, "First-line alectinib vs. brigatinib in advanced non-small cell lung cancer with ALK rearrangement : real-world data", Cancer Res Treat, 56, pp.61~69 (2024)
- Camidge DR, "Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC : final results of phase 3 ALTA-1L trial", J Thorac Oncol, 16, pp.2091~2108 (2021)
- Yang JC, "Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib : results of phase 3 ALTA-3 trial", J Thorac Oncol, 18, pp.1743~1755 (2023)
- Mok T, "Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study", Ann Oncol, 31, pp.1056~1064 (2020)
관련 논문AI추천
Emerging Ethical Issues in Managing Real World Data양광모대한의료정보학회 · Healthcare Informatics Research2019 · 제25권 제4호Present and Future of Utilizing Healthcare Data최인영대한의료정보학회 · Healthcare Informatics Research2023 · 제29권 제1호Assessment of adverse drug reactions encountered in primary care settingsKi Dong Ko대한가정의학회 · Korean Journal of Family Medicine2025 · 제46권 제6호Data-Driven Healthcare & Analytics in a Big Data World장혜정대한의료정보학회 · Healthcare Informatics Research2015 · 제21권 제1호A Personalized and Learning Approach for Identifying Drugs with Adverse Events허호, 고우진, 권영옥, 김범석, 신선균, 오옥희, 이정선, 천은경연세대학교의과대학 · Yonsei Medical Journal2017 · 제58권 제6호Comparative effectiveness research in observational studiesJaeun Choi대한치주과학회 · Journal of Periodontal & Implant Science2018 · 제48권 제6호
이 간행물의 다른 논문 (26건)
Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment안용찬pp. 699-699HER2-low Breast Cancer: Now and in the Future강소라, 김성배pp. 700-720Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP박세훈, 유창훈, 조영미, 김인호, 김형돈, 김한상, 이지은, 정현애, 이혜승, 김시현, 남수정, 김진원, 윤홍석, 이성영, 김지형, 김지현, 이충근, 김한조, 차용준, 김완섭, 전상훈, 심효섭, 임선민, 이인희, 김지훈, 홍숙희, 윤진아, 이아원, 천재경, 박소연, 김미소, 나기용, 윤선옥, 장기택, 박인근, 윤신교, 정재호pp. 721-742Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid TumorsSunil Sharma, 홍용상, 김정은, 류민희, 최창민, 김태원, 류백열, 강윤구, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Wernerpp. 743-750Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time BiasWanchen Zhai, Yun Fan, Ying Yu, Hui Li, Ning Chen, Sizhe Yu, Wanji Shenpp. 751-764